These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27431423)

  • 1. Gavi's policy steers country ownership and self-financing of immunization.
    Henderson K; Gouglas D; Craw L
    Vaccine; 2016 Aug; 34(37):4354-9. PubMed ID: 27431423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gavi's Transition Policy: Moving From Development Assistance To Domestic Financing Of Immunization Programs.
    Kallenberg J; Mok W; Newman R; Nguyen A; Ryckman T; Saxenian H; Wilson P
    Health Aff (Millwood); 2016 Feb; 35(2):250-8. PubMed ID: 26858377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of vaccine programs across 94 low- and middle-income countries.
    Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
    Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustainability of National Immunization Programme (NIP) performance and financing following Global Alliance for Vaccines and Immunization (GAVI) support to the Democratic Republic of the Congo (DRC).
    Le Gargasson JB; Breugelmans JG; Mibulumukini B; Da Silva A; Colombini A
    Vaccine; 2013 Apr; 31(15):1886-91. PubMed ID: 23462529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GAVI's challenges: funding and leadership.
    Lancet; 2010 Oct; 376(9751):1438. PubMed ID: 21036259
    [No Abstract]   [Full Text] [Related]  

  • 6. GAVI's funding challenge.
    Lob-Levyt J
    Lancet; 2010 May; 375(9727):1692-3. PubMed ID: 20472166
    [No Abstract]   [Full Text] [Related]  

  • 7. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
    Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
    Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Charting the evolution of approaches employed by the Global Alliance for Vaccines and Immunizations (GAVI) to address inequities in access to immunization: a systematic qualitative review of GAVI policies, strategies and resource allocation mechanisms through an equity lens (1999-2014).
    Gandhi G
    BMC Public Health; 2015 Nov; 15():1198. PubMed ID: 26621528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspective and investments in health system strengthening of Gavi, the Vaccine Alliance: a content analysis of health system strengthening-specific funding.
    Tsai FJ; Lee H; Fan VY
    Int Health; 2016 Jul; 8(4):246-52. PubMed ID: 26612851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gavi's balancing act: Accelerating access to vaccines while ensuring robust national decision-making for sustainable programmes.
    Sosler S; Kallenberg J; Johnson HL
    Vaccine; 2015 May; 33 Suppl 1():A4-5. PubMed ID: 25919172
    [No Abstract]   [Full Text] [Related]  

  • 11. Tracking donor funding towards achieving the Global Vaccine Action Plan (GVAP) goals: A landscape analysis (1990-2016).
    Ikilezi G; Zlavog B; Augusto OJ; Sherr K; Lim SS; Dieleman JL
    Vaccine; 2018 Nov; 36(49):7487-7495. PubMed ID: 30366804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routes Countries Can Take To Achieve Full Ownership Of Immunization Programs.
    McQuestion M; Carlson A; Dari K; Gnawali D; Kamara C; Mambu-Ma-Disu H; Mbwanque J; Kizza D; Silver D; Paatashvili E
    Health Aff (Millwood); 2016 Feb; 35(2):266-71. PubMed ID: 26858379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GAVI Alliance and the 'Gates approach' to health system strengthening.
    Storeng KT
    Glob Public Health; 2014; 9(8):865-79. PubMed ID: 25156323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
    Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
    Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategic donor behaviour and country vulnerability in health aid transitions.
    Mao W; McDade KK; Ogbuoji O; Yamey G; Bermeo SB
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 37940202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
    Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
    Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming challenges to sustainable immunization financing: early experiences from GAVI graduating countries.
    Saxenian H; Hecht R; Kaddar M; Schmitt S; Ryckman T; Cornejo S
    Health Policy Plan; 2015 Mar; 30(2):197-205. PubMed ID: 24510369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A global health partnership's use of time-limited support to catalyze health practice change: the case of GAVI's Injection Safety Support.
    Levin A; Fang A; Hansen PM; Pyle D; Dia O; Schwalbe N
    PLoS One; 2010 Sep; 5(9):e12986. PubMed ID: 20885995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.